Axcella Health Inc. (AXLA) Research

Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. in June 2016. Its operations are headquartered in Cambridge, Massachusetts.

Market snapshot

Symbol
AXLA
Price
$4.58
Day change
0.00%
Market cap
$12.5M
P/E ratio
-3.61x
52-week range
4.58-4.58
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$60.00

Peer companies

  • Applied Molecular Transport Inc. (AMTI)
  • Celyad Oncology S.A. (CYAD)
  • Gelesis Holdings, Inc. (GLS)
  • TuHURA Biosciences, Inc. (HURA)
  • Korro Bio, Inc. (KRRO)
  • Notable Labs, Ltd. (NTBL)
  • ObsEva S.A. (OBSV)
  • Reunion Neuroscience Inc. (REUN)

Recent insider activity

  • Koziel Margaret — S-Sale (679 shares) on 2023-03-01
  • Koziel Margaret — A-Award (70000 shares) on 2023-02-17
  • Hinshaw William — A-Award (275000 shares) on 2023-02-17
  • Fehlner Paul — A-Award (70000 shares) on 2023-02-17
  • Fehlner Paul — S-Sale (5221 shares) on 2023-02-10

Open Axcella Health Inc. (AXLA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.